Primary Merkel cell carcinoma (MCC) is a neuroendocrine tumor that typically affects older whites. It usually originates in the dermis, but in rare instances it has arisen in other primary sites, including the oral mucosa and the parotid gland. Explanations for the presence of MCC in these atypical locations have included theories of malignant transformation and neuroendocrine migration. We describe the case of a 35-year-old white woman who had an MCC in the parotid gland and no evidence of any other primary cutaneous lesion. A left superfi cial parotidectomy with facial nerve preservation was performed, and a histologic diagnosis of MCC was made. Positron-emission tomography was negative for other lesions, and postoperative radiation therapy was administered for local control. To the best of our knowledge, this is only the sixth case of a primary MCC of the parotid gland to be reported in the English-language literature; of these 6 patients, ours was by far the youngest. Otolaryngologists should be familiar with this rare but potentially fatal neoplasm.
Introduction
Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor that typically arises from the skin-specifi cally, from the Merkel cells in the basal layer of the epidermis. The presence of an MCC in the parotid gland is extremely rare. In fact, to the best of our knowledge, only 5 such cases have been previously reported in the English-language literature. [1] [2] [3] We describe a new case of parotid MCC, which was even more unusual in that our patient was much younger than the typical MCC patient.
Case report
A 35-year-old white woman presented to the otolaryngology offi ce complaining of a painless, rapidly growing mass on the left side of her jaw area of 1 month's duration. The patient had initially sought care from her primary care physician, who had prescribed azithromycin for 3 days and methylprednisolone for 1 week. When her condition did not improve, she underwent computed tomography (CT) with noniodinated intravenous contrast and was referred to our offi ce.
At presentation, the patient reported a slight enlargement of the mass. She denied trauma, recent travel, tuberculosis exposure, animal bites, and recent upper respiratory infections. She did not use tobacco or illegal drugs, and she drank alcohol occasionally. Her family history was negative for cancer. Her medication regimen at the time of presentation included bupropion, escitalopram, oxcarbazepine, pantoprazole, cetirizine, and some herbal supplements. She was allergic to iodine, penicillin, lithium, and shellfi sh.
Neck examination revealed a fi rm, mobile, 2-cm mass at the tail of the left parotid gland. The skin overlying the mass was normal and without erythema, and no other skin lesion or signifi cant lymphadenopathy was noted. On oral cavity and oropharyngeal examination, clear saliva fl owed freely from a noninfl amed Stensen duct on the left. Facial nerve function and facial sensation were normal. The CT showed a spherical 2-cm soft-tissue mass at the inferior pole of the left parotid gland (fi gure 1). No signifi cant lymphadenopathy was noted. A previously identifi ed 3 × 4-mm lung nodule in the posterolateral right lower lobe remained unchanged. Fine-needle aspiration cytology of the parotid mass revealed undifferentiated, small neoplastic cells and benign acinar cells.
A left superfi cial parotidectomy with facial nerve preservation was performed successfully. The lesion was fi rm, tan, and well circumscribed. Intraoperative frozen-section analysis of the mass and of a subcenti- meter lymph node revealed a possible lymphoma and a benign lymph node, respectively. Histologically, the tumor demonstrated a diffuse infi ltrative pattern with sheets of monotonous-appearing cells that formed illdefi ned nodules and trabecular cords (fi gure 2). The cells featured rounded nuclei with scant cytoplasm. The nuclei had fi nely dispersed chromatin with small nucleoli. Numerous mitoses and evidence of apoptosis were present. Immunohistochemical analysis revealed that the tumor cells were positive for the low-molecular-weight cytokeratins CK20 and CK56 and the neuroendocrine markers synaptophysin and chromogranin (fi gure 3). The histologic fi ndings were consistent with MCC. The tumor was negative for lymphoma (CD20 and CD3), small-cell carcinoma of the lung (thyroid transcription factor 1), and metastatic tumor (estrogen receptors, mammaglobin, p63, CK7, and AE1/AE3).
Postoperatively, the patient recovered without complication. A visual search for skin lesions and adenopathy was negative. Positron-emission tomography was negative for other lesions, as was testing for the presence of the human immunodefi ciency virus (HIV). In view of the aggressive nature of the tumor, radiation therapy to the parotid bed and neck for local control was recommended and subsequently completed.
Discussion
The incidence of MCC appears to be increasing, which is a refl ection of improvements in awareness, histo-pathologic methods, and new diagnostic instruments, techniques, and biomarkers. 4 In 2005, the annual ageadjusted incidence of MCC per 100,000 population was reported to be 0.23 for whites and 0.01 for blacks. 5 Most patients present between the ages of 68 and 70 years; only 5% of cases occur in patients younger than 50 years. [6] [7] [8] [9] The relatively young age of our patient made her case extraordinary. MCC typically appears as a red or violaceous nodule with a shiny surface, often with overlying telangiectasia. The most common locations are sun-exposed areas; 50% of tumors occur in the head and neck region. 10 Growth is typically rapid. In addition to sun exposure, other risk factors include smoking, alcohol intake, and trauma in mucosal sites, particularly the nasal, oral, pharyngeal, and laryngeal mucosa. 11 Gourin and Terris suggested that immunosuppression, especially in transplant patients, promotes a more aggressive course. 12 In fact, it has been reported that MCC occurs more frequently and at a younger age in chronically immunosuppressed patients, such as those with HIV infection. 13, 14 Because our patient was much younger than the typical MCC patient and because she had no other risk factors, HIV screening was warranted in this case.
Cutaneous MCC generally involves the dermis; fewer than 10% of cases involve the epidermis. 15 Atypical sites for primary tumors include several areas in the mucosa throughout the head and neck, 16 the sinonasal area, 17 and the parotid gland. 1 Szeder et al attributed the origin of MCC in neuroendocrine cells to the migration of neural crest cells to the skin, where they differentiate into mature Merkel cells. 18 Such a process would make it possible for MCCs to develop in various sites, including the parotid gland.
Another possible explanation for the development of MCCs at atypical sites is malignant transformation. Fornelli et al studied 2 patients with MCC of the pa-rotid gland, both of whom had no cutaneous primary tumor, and suggested that these tumors arose from the neuroendocrine component of a Warthin tumor. 1 Our review of the literature turned up reports of 3 other cases of neuroendocrine tumors of the parotid gland. 2, 3 Under electron microscopy, all 5 of these tumors demonstrated the features of MCC. However immunohistochemical staining was not performed in any of these cases, and thus the defi nitive cell type was not reported. Support for the theory of malignant transformation has been provided by studies of other types of tumor. Among these other tumors are lymphomas 19, 20 and carcinomas of glandular, 21 squamous, 22 and oncocytic 23 origin. Of course, another possible explanation is simple coincidence-that is, a benign tumor and a malignant tumor grow at the same time and in the same place. This explanation most likely would not pertain to our case because no other pathology was found. The metastatic potential of MCC to the parotid gland is a well-documented occurrence, and the skin is the most common primary site. 24, 25 This was considered in our patient.
Typically, MCC expresses both neuroendocrine markers (e.g., neuron-specifi c enolase, synaptophysin, and chromogranin) and cytokeratin markers (e.g., CK20 and CAM 5.2), but it is negative for S-100 protein and leukocyte common antigens. 10 The histologic differential diagnosis includes lymphoma, metastatic small-cell lung carcinoma, and lymphoepithelioma. The morphology and histochemistry of the tumor in our patient supported the diagnosis of MCC.
Treatment includes resection with 2-to 3-cm margins and radiation therapy to prevent locoregional recurrence. Chemotherapy has been recommended to prevent hematogenous and lymphatic spread, but no chemotherapy protocol has been shown to improve survival. [26] [27] [28] The prognosis for patients with MCC is poor, as the overall 5-year survival rate is only 47%. 4, 6, 7, 10 Because MCC is a very aggressive tumor, the probability of regional dissemination at diagnosis is high. Signifi cant positive prognostic factors include age younger than 65 years, female sex, and the absence of comorbidities. 4 Tumor site also infl uences survival; tumors in the truncal region are associated with the worst prognosis. Nodal disease is a powerful predictor of survival, and the overall survival rate for patients with nodal disease is typically half that of patients with localized disease. 29 The presence or absence of distant metastases is the most important factor in predicting survival; Gillenwater et al reported that 88% of MCC patients who developed a distant metastasis died of their disease. 30 Data on survival for patients with MCC at atypical sites are sparse. Research efforts directed at improving prognoses, explaining atypical sites of primary tumors, and defi ning treatments that might truly improve survival have all been greatly limited.
In conclusion, we report the case of the sixth and youngest patient to have had a documented case of a primary MCC of the parotid gland. Our search for possible metastatic disease to the parotid gland was negative. By reporting this case, we hope to contribute information that will eventually lead to a better understanding of the atypical origin of our patient's tumor. We also hope to eventually understand why she developed this aggressive tumor at such a young age.
